mutations and complicated kar yotype. It follows a linear evolution through the CLL clone from the recurrent acquisition of CDKN2ANot all people with CLL have to have therapy. Even with all new advancements, the iwCLL continue to recommends watchful observation for patients with asymptomatic sickness.86 This advice relies on no less than two random